The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | CLL treatment: statistical analysis in predictive medicine
Kevin Coombes, PhD, Ohio State University, Columbus, OH, discusses identifying biological subsets of chronic lymphocytic leukemia (CLL) patients that are likely to respond to fludarabine, cyclophosphamide, rituximab (FCR) treatment. Dr Coombes elaborates on the statistical techniques and models used to predict which groups would respond best to treatment. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
